Montreal Cognitive Assessment

Abstract

The Montreal Cognitive Assessment (MoCA) is a widely recognized, brief, performance-based cognitive screening instrument designed specifically to detect mild cognitive impairment (MCI) and early-stage neurodegenerative conditions in adult and geriatric clinical settings. Developed by Ziad Nasreddine and colleagues in Montreal, Quebec, Canada, the instrument addresses the clinical insensitivity and ceiling effects frequently observed with older screening batteries, such as the Mini-Mental State Examination (MMSE). The MoCA samples eight major neurocognitive domains across 30 scored elements: visuospatial abilities, executive functioning, confrontation naming, attention, concentration and working memory, language, abstract reasoning, short-term delayed recall, and spatiotemporal orientation. The standard paper-and-pencil version requires approximately 10 to 12 minutes to administer and yields an integer composite score ranging from 0 to 30 points. An educational adjustment adds one point for examinees with 12 or fewer years of formal schooling to mitigate educational bias. Psychometric evaluations across diverse international cohorts consistently reveal superior diagnostic accuracy: the original validation study demonstrated a sensitivity of 90% for detecting MCI and 100% for mild Alzheimer's disease, paired with a specificity of 87% among cognitively intact controls at the standard clinical cut-off score of 26. The instrument demonstrates robust internal consistency (Cronbach’s α ≈ .83), excellent test-retest stability (r = .92), and high inter-rater reliability. Structural equation modeling and factor analytic investigations confirm both a robust general cognitive ability dimension (g) and distinctive domain-specific loading patterns. Today, the MoCA serves as a primary cognitive metric in memory clinics, neurology services, neurorehabilitation, stroke units, and clinical trials worldwide.

Keywords

Montreal Cognitive Assessment, MoCA, Mild Cognitive Impairment, Neuropsychological Screening, Dementia, Executive Functioning, Episodic Memory, Psychometrics, Cognitive Screening, Validity

Authors

The Montreal Cognitive Assessment was conceived and developed by Dr. Ziad S. Nasreddine, MD, FRCPC, a Canadian behavioral neurologist and clinical researcher affiliated with the Department of Medicine at the University of Sherbrooke and McGill University, Montreal, Quebec, Canada. Dr. Nasreddine collaborated with an interdisciplinary research team comprising:

• Natalie J. Phillips, PhD — Department of Psychology, Concordia University, Montreal, Canada.
• Valérie Bédirian, MD — Memory Clinic, Hôpital Charles LeMoyne, Greenfield Park, Quebec, Canada.
• Simon Charbonneau, MSc — Neuropsychology Research Unit, Hôpital Charles LeMoyne, Quebec, Canada.
• Victor Whitehead, PhD — Department of Neurology and Neurosurgery, McGill University, Montreal, Canada.
• Ian Collin, MSc — Hôpital Charles LeMoyne, Quebec, Canada.
• Jeffrey L. Cummings, MD, ScD — Cleveland Clinic Lou Ruvo Center for Brain Health and Department of Neurotherapeutics, Las Vegas, Nevada, USA.
• Howard Chertkow, MD, FRCPC — Lady Davis Institute for Medical Research, Jewish General Hospital, and Department of Neurology, McGill University, Montreal, Canada.

The Dutch adaptation, highlighted in standard clinical guidelines in the Netherlands and Flanders, was translated, adapted, and validated by Dr. P. L. J. Dautzenberg (Geriatrician, Jeroen Bosch Ziekenhuis) and Dr. J. F. M. de Jonghe (Clinical Neuropsychologist, Medical Center Alkmaar) in 2004.

Purpose

The fundamental clinical and psychometric impetus behind the development of the Montreal Cognitive Assessment was the urgent need for a brief screening battery sensitive to the subtle neurobehavioral deficits that characterize Mild Cognitive Impairment (MCI). Prior to the MoCA's introduction, clinical evaluation in primary and secondary care relied heavily on the Mini-Mental State Examination (MMSE). While the MMSE is reasonably effective at identifying moderate-to-severe dementia, it exhibits pronounced ceiling effects among patients experiencing subtle functional, dysexecutive, or early amnestic changes. Consequently, individuals with early-stage neuropathology often scored within normal limits (26–30/30) on the MMSE, delaying clinical intervention and neuroprotective lifestyle or pharmacological strategies.

The MoCA was engineered to address this gap by establishing higher cognitive load demands and integrating subtests specifically dedicated to frontostriatal and dorsolateral prefrontal functions (such as mental set-shifting, working memory, and abstraction) alongside rigorous medial temporal lobe memory evaluations. Specifically, its goals include:

• Early Detection: Accurately discriminating cognitively intact older adults from those with amnestic MCI (aMCI) and non-amnestic MCI (naMCI), serving as a frontline diagnostic instrument in primary care, memory clinics, and geriatric outpatient services.
• Etiological Versatility: Assessing cognitive impairment in a wide spectrum of neurological, psychiatric, and systemic disorders beyond primary Alzheimer's pathology, including Parkinson's disease (PD-MCI and PD dementia), vascular cognitive impairment (VCI), post-stroke deficits, traumatic brain injury (TBI), multiple sclerosis, frontotemporal lobar degeneration, human immunodeficiency virus (HIV)-associated neurocognitive disorders, and major depressive disorder with pseudo-dementia features.
• Longitudinal Monitoring: Providing parallel forms (Versions 7.1, 7.2, and 7.3) that allow clinicians and researchers to track cognitive decline, natural disease progression, or therapeutic responses over time without confounding practice or test-retest learning effects.
• Standardized Research Metrics: Furnishing a standardized, quantifiable end-point metric for epidemiological research and randomized controlled trials evaluating neuroprotective, pharmacotherapeutic, or behavioral cognitive interventions.

Psychological Construct

The MoCA operationalizes global cognitive functioning through a multidimensional architecture composed of eight primary neurocognitive constructs. Rather than viewing cognition as an undifferentiated general capacity, the instrument evaluates distributed, functionally specialized brain networks:

1. Visuospatial and Executive Functioning

This composite domain measures higher-order cognitive control, cognitive flexibility, mental set-shifting, motor planning, and visuoconstructional praxis. Executive control relies heavily on the prefrontal cortex, frontostriatal circuits, and reciprocal connections to the parietal lobules. The subscale includes:

• Alternating Trail Making: A brief adaptation of the Trail Making Test Part B requiring the examinee to switch sequentially between numeric and alphabetical sequences (1-A-2-B-3-C-4-D-5-E), testing cognitive flexibility, set-shifting, and visual scanning.
• Visuoconstructional Cube Copy: Assessing three-dimensional spatial analysis, perceptual organization, and constructive praxis mediated by the right parietal and parieto-occipital cortices.
• Clock Drawing Task: Evaluating contour representation, spatial layout, semantic knowledge, and abstract planning by requiring the participant to draw a clock face with all digits and set the hands to a specific time ("11:10").

2. Confrontation Naming

The naming subtest assesses visual confrontation lexical retrieval and semantic memory integrity. The examinee must identify three low- to moderate-frequency animal figures (Lion, Rhinoceros, Camel). This task activates bilateral ventral visual processing streams (the "what" pathway) and left-hemispheric anterior and middle temporal language structures. Errors highlight visual agnosia, lexical retrieval failure, or degraded semantic networks often present in Alzheimer's disease and semantic variant primary progressive aphasia.

3. Attention, Concentration, and Working Memory

Reflecting capacity-limited active cognitive maintenance, this subscale assesses both sustained attention and the central executive component of working memory:

• Digit Span: Forward digit repetition (5 digits) evaluates the auditory-phonological loop and simple immediate attention; backward repetition (3 digits) taxes active mental manipulation and working memory capacity.
• Vigilance: A continuous performance task where the examinee taps their hand each time the target letter "A" is spoken within a semi-random acoustic letter sequence, assessing sustained auditory vigilance, tonic alertness, and selective inhibition.
• Serial 7s Subtraction: Requiring the examinee to sequentially subtract 7 from 100 over five successive iterations (93, 86, 79, 72, 65), measuring mental calculation, concentration, and active tracking across distracting intervals.

4. Language

This domain captures receptive and expressive grammatical, phonological, and semantic integrity via two tasks:

• Sentence Repetition: Repetition of two syntactically complex, low-frequency sentences ("I only know that John is the one to help today" and "The cat always hid under the couch when dogs were in the room"), assessing auditory-verbal repetition, phonological working memory, and syntactic processing.
• Phonemic Verbal Fluency: Generating words beginning with the letter "F" under a 60-second time limit (with a target criterion of ≥11 words). This task depends heavily on left dorsolateral prefrontal activation, strategic executive search, lexical retrieval, and self-monitoring.

5. Abstract Reasoning

Abstraction measures fluid conceptualization, semantic categorization, and inductive reasoning by requiring participants to determine the categorical commonality between semantic pairs (e.g., watch and ruler = measuring instruments; banana and orange = fruits). This task isolates concrete thinking and conceptual breakdown associated with frontal lobe dysfunction.

6. Short-Term Delayed Recall (Episodic Memory)

Episodic anterograde memory is evaluated using a five-item word list (Face, Velvet, Church, Daisy, Red). Words are presented across two immediate acquisition learning trials (not scored toward the total) followed by an unprompted delayed recall trial after a 5- to 10-minute distractor interval. If unprompted recall fails, clinical category prompts and multiple-choice options are administered to distinguish retrieval deficits (typical of subcortical-frontal dysfunction) from storage/consolidation failures (characteristic of hippocampal and entorhinal medial temporal damage).

7. Spatiotemporal Orientation

Autonoetic consciousness and orientation to time and space are evaluated by asking the examinee to state the exact date, month, year, day of the week, clinic/place, and city. Orientation relies on distributed cortical-hippocampal networks that support real-time environmental self-localization.

Theoretical Framework

The Montreal Cognitive Assessment is grounded in cognitive neuropsychology and behavioral neurology, integrating structural-functional brain mapping with cognitive architecture models. The instrument draws primarily on three theoretical frameworks:

1. Luria's Theory of Functional Brain Units

Alexander Luria's neurobehavioral model posits three functional units of the brain: (1) regulation of tone, waking, and mental states (reticular and subcortical structures); (2) receiving, analyzing, and storing information (posterior cortical areas: occipital, parietal, and temporal lobes); and (3) programming, regulating, and verifying conscious mental activity (frontal lobes, particularly prefrontal cortex). The MoCA samples all three units: sustained auditory attention captures Unit 1; naming, cube copying, and delayed recall assess Unit 2; and alternating trail making, letter fluency, and abstraction directly probe Unit 3. By covering all three systems, the battery identifies both focal cortical and diffuse subcortical neurodegenerative damage.

2. Baddeley's Working Memory Model

The subtests targeting attention and memory align with Alan Baddeley's multicomponent working memory model. The forward digit span and sentence repetition tasks index the phonological loop, while the backward digit span and Serial 7s subtests demand the coordination of the central executive. The cube copying and clock drawing tasks tap into the visuospatial sketchpad. This targeted structural breakdown provides granular insight into the specific cognitive systems affected in early neurodegenerative disorders.

3. The Hierarchy of Neurocognitive Decline in Aging

Early-stage neurodegenerative illnesses, such as Alzheimer's disease, typically show a progressive pathological hierarchy. Pathological tau deposition begins in the transentorhinal and hippocampal cortices (Braak stages I–II), spreading to polymodal association areas (Braak III–IV) before reaching neocortical regions (Braak V–VI). As a result, anterograde episodic memory consolidation breaks down earliest, followed by executive dysfunction, semantic retrieval decline, and visuospatial impairment, with temporal and spatial orientation failing last. The MoCA reflects this hierarchy: by stressing delayed memory consolidation without visual cues alongside prefrontal-dependent executive control, the instrument captures early pathological changes long before overlearned orientation responses begin to deteriorate.

Validity

The Montreal Cognitive Assessment has undergone extensive international clinical and psychometric validation, establishing high construct, criterion, convergent, and discriminant validity across diverse patient cohorts.

Criterion and Diagnostic Validity

In the seminal validation study by Nasreddine et al. (2005), the MoCA was evaluated in 94 healthy controls, 94 patients with mild cognitive impairment (MCI), and 93 patients with mild Alzheimer's disease (AD). Using the standard cut-off score of 26:

• Sensitivity: The MoCA detected 90% of individuals with MCI and 100% of individuals with mild AD. By contrast, the MMSE exhibited a sensitivity of only 18% for MCI and 78% for mild AD within the same clinical sample.
• Specificity: Specificity was 87% among cognitively intact elderly controls.
• Positive and Negative Predictive Values: Positive predictive values (PPV) and negative predictive values (NPV) for MCI were 89% and 91%, respectively, demonstrating robust diagnostic accuracy.

Subsequent meta-analyses (e.g., Ciesielska et al., 2016; Davis et al., 2015) confirm that the MoCA consistently outperforms the MMSE for detecting MCI across diverse clinical settings, maintaining receiver operating characteristic (ROC) area under the curve (AUC) values ranging from .84 to .95.

Convergent and Discriminant Validity

The MoCA demonstrates strong convergent validity when compared against comprehensive, multi-hour neuropsychological test batteries and established clinical rating tools:

• Correlations with the MMSE typically range between r = .78 and .86 in mixed clinical and non-clinical samples.
• MoCA memory subscores correlate significantly with formal episodic memory measures, such as the Rey Auditory Verbal Learning Test (RAVLT; r = .65 to .74) and the California Verbal Learning Test (CVLT).
• Executive subcomponents (Alternating Trail Making, Letter Fluency) correlate well with the Delis-Kaplan Executive Function System (D-KEFS) and the standard Trail Making Test Part B (r = −.55 to −.68).

Discriminant validity is supported by the MoCA's ability to differentiate between normal cognitive aging, mild cognitive impairment, and dementia, as well as its capacity to separate distinct clinical phenotypes. For example, individuals with frontotemporal lobar degeneration or vascular cognitive impairment typically demonstrate severe deficits in executive and fluency subscores with relatively preserved delayed memory, whereas patients with early amnestic Alzheimer's disease present with the inverse profile.

Cross-Cultural and Demographic Adjustments

Extensive international validation studies (including Dutch, German, French, Spanish, Chinese, and Arabic adaptations) highlight the influence of age and educational attainment on MoCA total scores. The standard 1-point addition for individuals with 12 or fewer years of education addresses this variable in part, though epidemiological research in low-literacy or heterogeneous populations often recommends education-stratified cut-off scores (e.g., cut-offs of 22 to 24) to reduce false-positive diagnoses while preserving high diagnostic specificity.

Reliability

The psychometric reliability of the Montreal Cognitive Assessment has been established across multiple dimensions, including internal consistency, test-retest stability, inter-rater concordance, and alternate-form equivalence:

Internal Consistency

In the original validation study (Nasreddine et al., 2005), internal consistency for the complete 30-point instrument was high, yielding a Cronbach's alpha (α) of .83 across healthy controls, MCI patients, and AD cohorts. Independent validation studies across varied clinical populations report alpha values generally ranging between .78 and .88, demonstrating balanced item homogeneity while covering diverse cognitive domains.

Test-Retest Reliability

Temporal stability is high across both short and intermediate retest intervals. Nasreddine et al. observed an overall test-retest reliability coefficient of r = .92 over an average interval of 35.0 ± 17.6 days among healthy participants and stable clinical subjects. The mean difference between the initial assessment (mean = 28.02) and repeat evaluation (mean = 28.32) was minimal (Δ = 0.3 points), demonstrating negligible practice effects when using standard administration procedures.

Inter-Rater Reliability

Because the MoCA incorporates performance-based tasks requiring subjective scoring (e.g., the Clock Drawing Task, the Visuoconstructional Cube, and Abstract Reasoning), inter-rater reliability is essential. Studies using paired, blind scoring by independent neuropsychologists and trained medical professionals report inter-rater intraclass correlation coefficients (ICCs) between .91 and .97. Strict adherence to standardized administration instructions ensures consistent scoring across examiners and clinical settings.

Alternate-Form Reliability

To support longitudinal cognitive monitoring in clinical trials and routine follow-ups, two alternate forms (MoCA Versions 7.2 and 7.3) were developed to parallel the original Version 7.1. Alternate versions use parallel items with matched psychometric difficulty (e.g., substituting alternative animals for naming, alternate word lists for delayed recall, and different letter sequences for vigilance). Equivalence studies indicate that correlation coefficients between the alternate forms range from .87 to .92, with non-significant mean total score differences (typically <0.5 points) when administered in counterbalanced order.

Factor Analysis

Factor analytic studies of the MoCA clarify its latent structural organization, demonstrating that the instrument captures both a unified general cognitive factor (g) and distinctive, domain-specific neurocognitive components.

Exploratory Factor Analysis (EFA)

Exploratory factor analyses across general geriatric, stroke, and memory clinic populations (e.g., Freitas et al., 2012; Julayanont et al., 2014) commonly reveal multidimensional factor models extracting between 2 and 6 underlying latent dimensions, depending on whether items are evaluated as individual subtests or composite domain scores. Standard EFA solutions typically isolate three to four primary factors:

• Factor 1: Memory and Delayed Retrieval — Heavily loaded by Delayed Word Recall items and orientation subtests.
• Factor 2: Executive Control and Attention — Characterized by high loadings from Alternating Trail Making, Backward Digit Span, Serial 7s Subtractions, and Phonemic Verbal Fluency.
• Factor 3: Visuoperceptual / Constructive Abilities — Defined by the Cube Copy, Clock Drawing contour/numbers/hands, and Confrontation Naming.
• Factor 4: Language and Abstract Conceptualization — Comprising Sentence Repetition, Phonemic Fluency, and Category Similarity tasks.

Confirmatory Factor Analysis (CFA) and Bifactor Modeling

Confirmatory factor analyses testing competing structural models demonstrate that a bifactor model—incorporating a general cognitive efficiency factor alongside domain-specific group factors—provides the best fit to empirical data (e.g., Kopecek et al., 2017; Marioni et al., 2011). In bifactor modeling:

• The general cognitive factor accounts for a substantial proportion of common variance (>65–75%), supporting the use of the single total composite score (0–30) in routine clinical screening.
• Fit indices for bifactor and higher-order models regularly fall within accepted psychometric standards: Comparative Fit Index (CFI) ≥ .94, Tucker-Lewis Index (TLI) ≥ .92, Root Mean Square Error of Approximation (RMSEA) ≤ .045 to .055, and Standardized Root Mean Square Residual (SRMR) ≤ .050.

Item Response Theory (IRT) and Rasch modeling analyses further demonstrate that the MoCA's items span a wider difficulty spectrum than the MMSE. Delayed Recall and Alternating Trail Making items exhibit high discriminative power at the threshold between normal cognitive aging and MCI, confirming the instrument's structural utility for detecting early neurocognitive decline.

Instrument / Measurement Tool

• Test Type: Performance-based neurocognitive screening instrument; clinician-administered paper-and-pencil or authorized digital battery.
• Format: One-page structured protocol comprising direct performance tasks, verbal generation tests, and behavioral response items.
• Target Population: Adults and older adults suspected of cognitive decline, Mild Cognitive Impairment, Alzheimer's disease, or secondary cognitive impairment associated with neurological conditions (stroke, Parkinson's disease, traumatic brain injury).
• Administration Time: Approximately 10 to 12 minutes (extendable up to 15 minutes in complex neurological cases).
• Item Count: 33 distinct subtest elements organized into 8 cognitive domains, yielding a cumulative maximum total score of 30 points.
• Subscale Point Allocation:
  • Visuospatial / Executive Functioning: 5 points total (Trail Making: 1 point; Cube Copy: 1 point; Clock Drawing: 3 points [Contour = 1, Numbers = 1, Hands = 1]).
  • Naming: 3 points total (1 point per correctly identified animal).
  • Attention: 6 points total (Digit Span Forward: 1 point; Digit Span Backward: 1 point; Vigilance/Tapping: 1 point; Serial 7s: 0–3 points based on correct subtractions [4–5 correct = 3 pts, 2–3 correct = 2 pts, 1 correct = 1 pt, 0 correct = 0 pts]).
  • Language: 3 points total (Sentence Repetition: 2 points [1 point per sentence]; Verbal Fluency: 1 point [≥11 words in 60s]).
  • Abstraction: 2 points total (1 point per correct categorical relationship).
  • Delayed Recall: 5 points total (1 point per word recalled spontaneously without cues).
  • Orientation: 6 points total (1 point each for Date, Month, Year, Day of the week, Place, City).
• Response Scale: Point-based performance scoring (Total score ranges from 0 to 30 points; 1 extra point added for individuals with 12 or fewer years of education).
• Educational Correction Rule: If the subject has completed 12 years or fewer of formal education, 1 point is added to the total composite score (provided the pre-adjustment score is <30).
• Diagnostic Interpretation & Clinical Cut-offs:
  • Score 26 – 30: Considered normal cognitive performance.
  • Score 18 – 25: Typically indicative of Mild Cognitive Impairment (MCI) or mild neurocognitive dysfunction.
  • Score 10 – 17: Suggestive of moderate cognitive impairment / mild-to-moderate dementia.
  • Score < 10: Indicative of severe cognitive impairment / advanced dementia.

Permissions & Fee and Test Year

The Montreal Cognitive Assessment was developed in 1996 and formally validated in its definitive landmark publication in 2005 by Dr. Ziad Nasreddine and colleagues. The Dutch validation was published by Dr. P. L. J. Dautzenberg and Dr. J. F. M. de Jonghe in 2004.

Licensing, Training, and Certification: The MoCA is copyrighted by Dr. Ziad Nasreddine and MoCA Test Inc. While the test protocol was originally distributed freely in the public domain for clinical and educational purposes, MoCA Test Inc. instituted an official training and certification policy in 2019–2020. Clinicians, neuropsychologists, and researchers administering the test must complete an accredited formal certification program accessible through the official portal (www.mocatest.org). The certification requires a one-time fee, with credential renewals or recertifications according to institutional protocols.

Clinical vs. Commercial / Research Use: Non-profit academic research and accredited individual clinical use operate under specific licensing arrangements managed through MoCA Test Inc. Funded clinical trials, pharmaceutical studies, and commercial applications require formal written licensing agreements and per-administration licensing fees from the copyright holder.

References

• Ciesielska, N., Sokołowski, R., Mazur, E., Podhorecka, M., Polak-Szabela, A., & Kędziora-Kornatowska, K. (2016). Is the Montreal Cognitive Assessment (MoCA) test better than the Mini-Mental State Examination (MMSE) in the detection of mild cognitive impairment (MCI) in the elderly? An analysis of literature. European Journal of Medical Research, 21(1), Article 45. https://doi.org/10.1186/s40001-016-0240-3
• Dautzenberg, P. L. J., & de Jonghe, J. F. M. (2004). De Montreal Cognitive Assessment (MoCA): Een nieuw screeningsinstrument voor milde cognitieve stoornissen. Tijdschrift voor Gerontologie en Geriatrie, 35(3), 118–121.
• Davis, D. H., Creavin, S. T., Yip, J. L., Noel-Storr, A. H., Brayne, C., & Cullum, S. (2015). Montreal Cognitive Assessment for the diagnosis of Alzheimer's disease and other dementias. Cochrane Database of Systematic Reviews, 2015(10), CD010775. https://doi.org/10.1002/14651858.CD010775.pub2
• Freitas, S., Simões, M. R., Alves, L., & Santana, I. (2012). Montreal Cognitive Assessment (MoCA): Psychometric properties of the Portuguese version in a sample of mild cognitive impairment and Alzheimer's disease patients. The Clinical Neuropsychologist, 26(2), 263–279. https://doi.org/10.1080/13854046.2012.656847
• Julayanont, P., Brousseau, M., Chertkow, H., Phillips, N., & Nasreddine, Z. S. (2014). Montreal Cognitive Assessment Memory Index Score (MoCA-MIS) as a predictor of conversion from mild cognitive impairment to Alzheimer's disease. Journal of the American Geriatrics Society, 62(4), 679–684. https://doi.org/10.1111/jgs.12742
• Kopecek, M., Stepankova, H., Lukavsky, J., Ripova, D., & Nikolai, T. (2017). Montreal Cognitive Assessment (MoCA): Normative data for Czech elderly and factor structure. Journal of Clinical and Experimental Neuropsychology, 39(10), 978–989. https://doi.org/10.1080/13803395.2017.1296937
• Marioni, R. E., Chatfield, M., Brayne, C., & Matthews, F. E. (2011). The reliability of the Montreal Cognitive Assessment in a longitudinal population-based study of aging. International Journal of Geriatric Psychiatry, 26(8), 847–853. https://doi.org/10.1002/gps.2613
• Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J. L., & Chertkow, H. (2005). The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. Journal of the American Geriatrics Society, 53(4), 695–699. https://doi.org/10.1111/j.1532-5415.2005.53221.x

Items of the Scale